Smith & Nephew SNATS (SNN) Stock Analysis & Forecast

Nov 13 close

$31.28+0.28 (+0.9%)

Gekko Brief

AI summaryNov 9 close

Smith & Nephew's week was shaped by the collapse of its potential $34 billion merger with Johnson & Johnson's orthopaedics business, which has turned attention toward its existing wound care line, including SANTYL. Alongside this, the company's Q3 2026 trading report showed strong Sports Medicine & ENT performance offset by weaker-than-expected US knee and hip sales, prompting a cut to full-year underlying revenue growth guidance to 3% and a halving of expected trading profit growth to around 4%. This guidance revision also drew a rating downgrade from one analyst citing credibility concerns despite recent share price gains.

SNN closed at $31.05, down 0.3%, sitting between its 50-day average of $28.55 and its 200-day average of $31.02. The GekkoIndex reads 47.3, placing the stock in the Neutral zone. Shares trade 4.5% below Gekko Fair Value of $32.52, within the range the checklist treats as close to fair value.

The next earnings date falls on 1 March 2027, 111 days out and beyond a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the current window. Seasonally, the next 20 trading days have averaged a 2.5% gain over 5 years, rising in 4 of them. Among four covering firms, all four rate the stock hold, with a consensus target of $32.32, implying 4.1% upside from current levels.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Smith & Nephew SNATS price vs fair value

$31.84$31.28Nov ’25May ’26Nov ’26
Close $31.28200-day averageGekko Fair Value $31.84

Smith & Nephew SNATS quick facts

Market cap
$13.09B
P/E ratio
21.4
Forward P/E
11.2
EPS, TTM
$1.47
Revenue, TTM
$6.30B
Profit margin
10.1%
Dividend yield
2.56%
Beta
0.67
Volume
1.37M avg 1.53M
1-year return
−6.5%
Typical daily move
±2.4%
Typical 20-day move
±4.9%
50-day average
$28.73
200-day average
$30.96
Next earnings
Mar 1
Shares outstanding
418.5M
52-week range
$26.12$37.09

Smith & Nephew SNATS swing-trade checklist

Smith & Nephew SNATS scores 2 supportive, 3 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive3 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $31.28 sits between the 50-day ($28.73) and 200-day ($30.96) averages, or the averages disagree.

    See the chart
  • GekkoIndexmixed

    50.2, Neutral

    Reading 50.2 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    1.8% below

    Price is within 5% of Gekko Fair Value (1.8% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 106 days

    Next report Mar 1, 2027, 106 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +1.3% on average

    From this point in the calendar, the next 20 trading days averaged +1.3% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Smith & Nephew SNATS stock chart and price history

Smith & Nephew SNATS closed at $31.28 on Nov 13, 2026, −6.5% over the past year, inside a 52-week range of $26.12 to $37.09.

Close50-day average200-day averageVolume
Smith & Nephew SNATS share price, past year, with 50-day and 200-day moving averages and volume$26$28$30$32$34$36DecJan 2026FebMarAprMayJunJulAugSepOctNov31.28

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+7.5%
3 months
+5.4%
6 months
+5.9%
1 year
−6.5%
The full SNN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SNN in Gekko

Follow Smith & Nephew SNATS through every session

Put SNN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track SNN in GekkoFree for 7 days. No credit card required.

About Smith & Nephew SNATS

Smith & Nephew SNATS develops, manufactures and sells medical devices and related services used in surgery and wound care, reaching healthcare providers in the United Kingdom, the United States and other markets. It is recognized for products supporting joint replacement, sports medicine procedures and the treatment of wounds ranging from minor injuries to chronic ulcers and burns.

The company organizes its work across three areas: orthopaedics, sports medicine and ENT, and advanced wound management. Its orthopaedics offerings include knee and hip implants along with trauma and extremities devices for stabilizing fractures and correcting deformities. The sports medicine and ENT segment supplies instruments and implants for minimally invasive joint repair, along with visualization and tissue resection tools used during arthroscopic surgery, plus ear, nose and throat products. The wound management segment covers dressings and devices for acute and chronic wounds, along with bioactive and regenerative products such as skin and bone graft substitutes, all sold to hospitals and other healthcare providers.

Smith & Nephew SNATS traces its founding to 1856 and is headquartered in Watford, in the United Kingdom. Its shares trade under the ticker SNN.

Sector
Health technology
Website
smith-nephew.com

Smith & Nephew SNATS GekkoIndex: the smart money zone

Smith & Nephew SNATS’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.2, in the Neutral zone, up 6 points over five sessions.

010050.2Neutral

Up 6 points over five sessions, from the Distribution zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying53+0.9%+1.4%+0.9%+2.6%
Accumulation2320.0%+0.4%+0.8%+3.1%
Neutral (current zone)335+0.3%+0.3%+0.8%+0.7%
Distribution35+0.2%+1.0%+2.7%+4.4%
Selling0Not available

Average SNN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the SNN price, zone by zone.Track SNN in Gekko

Is Smith & Nephew SNATS stock overvalued? Gekko Fair Value

Smith & Nephew SNATS trades 1.8% below Gekko Fair Value of $31.84, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Smith & Nephew SNATS shares are worth, recalculated every trading day.

$31.84

Gekko Fair Value, Nov 14, 2026

1.8% below fair value · About fair value

At the end of Aug 2026 the price was 10.6% below the estimate.

Gekko Fair ValueShare price, month end
$32$31Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open SNN in Gekko

Smith & Nephew SNATS insider and Congress trading

No open-market insider purchases were filed for Smith & Nephew SNATS, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for SNN in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every SNN insider filing, plotted on the chart in Gekko.Open SNN in Gekko

Congress trades last 90 days

No trades in SNN were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for SNN, plotted on the chart in Gekko.Open SNN in Gekko

Buybacks

Smith & Nephew SNATS has been buying back its own shares.

Bought back, quarter ended Jun 27, 2026
$116.0M
As a share of market cap
0.89%

From company filings.

Hedge funds and billionaires quarter ended Sep 30

0of the funds Gekko tracks hold SNN.

0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Smith & Nephew SNATS earnings: next date and track record

Smith & Nephew SNATS reports on Mar 1, 2027 (106 days away).

Smith & Nephew SNATS stock forecast and analyst price targets

Analysts’ average 12-month price target for Smith & Nephew SNATS is $33.19, +6.1% from the last close, from 3 firms rating the stock in the last 90 days.

$33.19consensus 12-month target, +6.1% from the last close
Buy0
Hold3
Sell0

Each firm’s latest rating in the last 90 days: 3 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 9BTIGHold, maintained——
Nov 5Canaccord GenuityHold, maintained$33+5.5%
Nov 4Bank of America SecuritiesHold, maintained——
Nov 4BTIGHold, maintained——
Oct 6Bank of America SecuritiesHold, reiterated$14.58−53.4%
+0.8%average 20-day move after past Neutral readings
+1.3%average move over the next 20 trading days in the last 5 years
±2.4%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Smith & Nephew SNATS seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Smith & Nephew SNATS averaged +1.3% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−10.8%2021+11.1%2022+4.0%2023+3.6%2024−1.4%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−0.1%3 of 5
Next 10 trading days−0.3%4 of 5
Next 15 trading days+1.1%4 of 5
Next 20 trading days+1.3%3 of 5
Next 30 trading days+2.1%4 of 5

For scale, SNN’s typical 20-trading-day move in either direction is about 4.9%.

Smith & Nephew SNATS market cap and key statistics

Smith & Nephew SNATS’s market cap is $13.09B, with a P/E ratio of 21.4 and revenue of $6.30B over the last twelve months.

Valuation

Market cap
$13.09B
P/E ratio
21.4
Forward P/E
11.2
EPS, TTM
$1.47
Gekko Fair Value
$31.84

Trading

Volume
1.37M
Avg volume, 20 days
1.53M
52-week high
$37.09
52-week low
$26.12
Shares outstanding
418.5M

Financials

Revenue, TTM
$6.30B
Profit margin
10.1%
Return on equity
11.8%
Quarterly earnings growth, YoY
+5.7%

Risk and income

Beta
0.67
Typical daily move
±2.4%
Typical 20-day move
±4.9%
Dividend yield
2.56%

Smith & Nephew SNATS stock news this week

Coverage of Smith & Nephew SNATS this week reads neutral: 1 positive, 2 neutral and 1 negative headlines.

News sentiment neutral

More stocks

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Health technology

Smith & Nephew SNATS stock FAQ

What is Smith & Nephew SNATS’s market cap?

Smith & Nephew SNATS’s market cap is $13.09B at the Nov 13, 2026 close of $31.28, with 418.5M shares outstanding. The shares trade on a P/E ratio of 21.4.

What is the Smith & Nephew SNATS stock forecast?

The consensus analyst 12-month price target for Smith & Nephew SNATS is $33.19, +6.1% from the last close. Of the 3 firms that rated the stock in the last 90 days, 0 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Smith & Nephew SNATS stock overvalued or undervalued?

On Gekko’s estimate Smith & Nephew SNATS is about fair value: the Nov 13, 2026 close of $31.28 is 1.8% below Gekko Fair Value of $31.84. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Smith & Nephew SNATS report earnings next?

Smith & Nephew SNATS is expected to report on Mar 1, 2027 (106 days away). Analysts expect earnings of $1.20 per share on revenue of $3.31B.

What is Smith & Nephew SNATS’s 52-week high and low?

Smith & Nephew SNATS’s 52-week high is $37.09 and its 52-week low is $26.12; it closed at $31.28 on Nov 13, 2026, −6.5% over the past year. Over the last five years the shares peaked at $38.79 on Sep 9, 2025.

Is Smith & Nephew SNATS stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (earnings risk and seasonality), 3 as mixed (trend, gekkoindex and fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Smith & Nephew SNATS the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.